• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

FDA Releases COVID-19 Response At-A-Glance Summary

americanpharmaceuticalreviewSeptember 17, 2020

Tag: FDA , COVID-19 , Response At-A-Glance

The U.S. Food and Drug Administration (FDA), along with other federal, state, and local agencies and public health officials across the country, continues critical work to protect public health during the pandemic of COVID-19. To help track updates, the FDA has released a “Response At-A-Glance” document.

Major focus areas of the FDA’s response include increasing the availability of tests, therapeutics, and other devices such as ventilators and personal protective equipment, and many other important items necessary for the response. The FDA is also monitoring the human and animal food supply and taking swift action on fraudulent COVID-19 products.

Previous:Australia enters $1.2bn Covid-19 vaccine supply agreement

Next:Liminal BioSciences Resubmits BLA for Ryplazim for Congenital Plasminogen Deficiency

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

FDA Releases COVID-19 Response At-A-Glance Summary | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Deltamine (FDA)

Deltamine (FDA)
Etoposide( FDA)

Etoposide( FDA)
Thiophosphoramide (FDA)

Thiophosphoramide (FDA)
Prednisolone (FDA /COS)

Prednisolone (FDA /COS)
Hemisuccinate /Sodium (FDA/DMF)

Hemisuccinate /Sodium (FDA/DMF)
Hexafluorodianhydride(6-FDA)

Hexafluorodianhydride(6-FDA)
Praziquantel (FDA)

Praziquantel (FDA)
Dobutamine HCL (FDA)

Dobutamine HCL (FDA)
Cilostazol(FDA Approved) (Micronized)

Cilostazol(FDA Approved) (Micronized)
Clindamycin Phosphate( FDA)

Clindamycin Phosphate( FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service